Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 15;17(3):726–739. doi: 10.20892/j.issn.2095-3941.2020.0073

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © 2020, Cancer Biology & Medicine

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Potential mechanisms of drug resistance in MCL. (A) Secretory protein and extracellular matrix related drug resistance. Microenvironment cells protected malignant B cells from drug resistance by secreting proteins and extracellular matrix. (B) Cell surface receptors associated with drug resistance. Cell surface receptors bound to drugs, thus reducing drug concentrations in cells and diminishing the toxicity of drugs to cancer cells. (C) Drug resistance related to drug metabolism. Drug metabolic pathways led to drug resistance. (D) Survival promotion and DNA damage repair related to drug resistance. Malignant B cell resistance induced by DNA damage repair and survival promotion. (E) Cancer gene related drug resistance. Malignant B cells promoted their survival by inhibiting the activity of tumor suppressor proteins, thus resulting in drug resistance.